Clinical Trial Update: A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A 12-week Phase 2 study assessing the efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GW856553

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED